Global IVF Devices and Consumables Market Size, Share & Trends Analysis Report By Product Type (IVF Devices Incubators Micromanipulators Cryopreservation Equipment Imaging Systems (e.g., Time-Lapse Imaging) Others (IVF Workstations, Laser Systems) , IVF Consumables Culture Media Petri Dishes and Plates Catheters Syringes and Needles Disposable Gloves Other Consumables (Pipettes, Vials, Straws, etc.) ), By Application (Assisted Reproductive Technology (ART) , Fertility Clinics , Re

IVF Devices and Consumables Market Size

Global IVF Devices and Consumables Market size is projected at USD 4,141.55 million in 2026 and is expected to hit USD 15,136.90 million by 2034 with a CAGR of 17.7%. The market was valued at USD 3,522.16 million in 2025, indicating an absolute forecast-period increase of USD 10,995.35 million. Detailed assessment of product segmentation, clinical utilization, technology adoption, geographic concentration and competitive positioning is essential as fertility laboratories increasingly combine capital equipment, disposable products, imaging, cryopreservation and embryo-culture workflows.

Key Takeaways

• North America dominates the regional structure with USD 1,629.62 million in 2026, equivalent to approximately 39.3%, while Middle East and Africa records the fastest regional CAGR at 18.05%.
• Europe accounts for approximately 29.3% of 2026 regional revenue, followed by APAC at 16.8%, Middle East and Africa at 8.3%, and Latin America at 6.2%.
• IVF Devices dominate product revenue at USD 2,671.08 million in 2026, representing approximately 64.4% of the product-table total, and record the faster 17.85% CAGR.
• IVF Consumables account for USD 1,476.02 million in 2026, approximately 35.6% of the product-table total, and are forecast at a 17.55% CAGR.
• APAC, containing major emerging IVF economies including China and India, reaches USD 2,561.38 million by 2034 at 17.72% CAGR; the supplied dataset does not separately quantify individual-country forecasts.

The market comprises incubators, micromanipulators, cryopreservation equipment, imaging platforms, workstations, culture media, catheters, dishes, pipettes and other products supporting IVF and ART laboratories. On the supplied product basis, devices contribute 64.4% and consumables 35.6% of 2026 revenue. On the regional basis, North America contributes 39.3% and Europe 29.3%. Clinical throughput remains substantial: U.S. providers performed 435,426 ART cycles and 206,304 embryo-transfer cycles in 2022, while 94,039 live-birth deliveries were reported.

IVF Devices and Consumables Market Trends

Automation, Closed Incubation and Digital Embryo Assessment

IVF laboratories are shifting toward integrated incubation, time-lapse imaging, automated assessment and digitally traceable workflows. A 2025 embryo-grading study used more than 2,500 time-lapse videos, illustrating the expanding dataset scale behind AI-assisted embryo evaluation. In the U.S., 85.9% of embryo transfers were single-embryo transfers in 2022, while 42.6% of ART cycles involved egg or embryo banking, reinforcing requirements for cryostorage, imaging and standardized handling.

Cryopreservation is becoming increasingly embedded in routine treatment. UK frozen embryo transfers increased from 24% of IVF cycles in 2014 to 48% in 2024, while egg and embryo freezing represented 17% of treatment and freezing cycles. Approximately 64,000 UK patients underwent more than 100,000 cycles in 2024, with IVF representing 76% of clinic activity.

IVF Devices and Consumables Market Drivers

Rising ART Procedure Volumes and Laboratory Intensification

Higher ART throughput directly increases utilization of media, dishes, catheters, needles, incubators and cryopreservation systems. U.S. ART cycles increased from 190,840 in 2013 to 435,426 in 2022, a rise of approximately 128%, while live-birth deliveries increased from 54,351 to 94,039. Banking cycles expanded from 27,564 to 184,423 over the same period, creating particularly strong utilization intensity for cryogenic and disposable laboratory products.

IVF Devices and Consumables Market Restraints

High Treatment Costs, Quality Requirements and Capital Intensity

IVF laboratories require controlled temperature, gas, imaging and sterile handling systems, creating meaningful acquisition and compliance costs. Clinical outcomes also remain variable: U.S. ART cycles produced live-birth delivery in 37.5% of cases in 2022, while patient age averaged 36.3 years. Quality failures can carry substantial consequences, increasing supplier qualification, validation and regulatory costs across thousands of treatment cycles.

IVF Devices and Consumables Market Opportunities

Cryopreservation, AI Imaging and Integrated Laboratory Platforms

Expansion of frozen-transfer workflows creates opportunities across vitrification, storage and imaging. UK frozen embryo transfers reached 48% of IVF cycles in 2024 versus 24% in 2014, while embryo-freezing cycles increased from approximately 1,900 in 2014 to 10,450 in 2024. Esco Medical's 2025 MIRI M system introduced up to 18 independent chambers capable of maintaining controlled conditions while undocked for up to 30 minutes, highlighting equipment innovation around workflow stability.

Challenges in Global IVF Devices and Consumables Market

Standardization Across High-Complexity IVF Laboratories

Suppliers must support repeatable performance across increasingly complex clinical workflows. In 2022, 28.0% of U.S. ART cycles cited male-factor infertility, 26.2% diminished ovarian reserve and 18.3% preimplantation genetic testing, while 85.9% of transfers used single embryos. Such clinical heterogeneity raises requirements for validation, traceability, media consistency and interoperability among multiple laboratory systems.

IVF Devices and Consumables Market Segmentation

Product segmentation shows clear equipment dominance: IVF Devices represent approximately 64.4% of 2026 product revenue versus 35.6% for IVF Consumables. The supplied product table totals USD 4,147.10 million in 2026 and USD 15,319.69 million in 2034, differing from the separately supplied regional totals of USD 4,141.55 million and USD 15,136.90 million; both datasets are retained without alteration.

By Product Type

IVF Devices are the largest category at USD 2,671.08 million in 2026 and USD 9,938.57 million by 2034, advancing at 17.85% CAGR. The category includes incubators, micromanipulators, cryopreservation equipment, time-lapse imaging systems, workstations and laser systems.

IVF Consumables increase from USD 1,476.02 million in 2026 to USD 5,381.12 million in 2034 at 17.55% CAGR. Culture media, dishes, plates, catheters, needles, gloves, pipettes, vials and straws generate recurring demand, while IVF Devices remain the faster-growing supplied product segment at 17.85%.

By Application

Applications comprise ART, fertility clinics, research institutes, hospitals and surgical centers. The supplied dataset does not allocate application-level revenue or CAGR; consequently, no unsupported subsegment value is assigned. Overall product-table revenue progresses from USD 4,147.10 million in 2026 to USD 15,319.69 million in 2034 at 17.7%.

ART and fertility-clinic workflows are expected to remain central because each cycle requires multiple equipment and disposable touchpoints. U.S. data recorded 435,426 ART cycles and 206,304 embryo transfers in 2022, demonstrating the procedural intensity supporting application demand.

By End Use

Fertility clinics, hospitals, research laboratories and diagnostic centers constitute the principal end users. No end-use revenue or CAGR is supplied; therefore, the report does not fabricate dominance percentages. The available product dataset establishes USD 4,147.10 million for 2026 and a 17.7% overall CAGR.

Clinic utilization remains the principal commercial interface because IVF workflows combine incubation, manipulation, embryo culture, imaging and cryostorage. UK licensed clinics managed more than 100,000 treatment and freezing cycles for approximately 64,000 patients during 2024.

By Technology

Technology segmentation includes conventional IVF, ICSI, cryopreservation and time-lapse imaging. No technology-specific revenue or CAGR was provided; the overall supplied forecast remains 17.7%, with product revenue reaching USD 15,319.69 million by 2034.

Cryopreservation and imaging show particularly visible clinical adoption signals: frozen embryo transfers represented 48% of UK IVF cycles in 2024, twice the 24% level recorded in 2014. AI research datasets exceeding 2,500 time-lapse embryo videos further demonstrate digitalization of embryo assessment.

By Distribution Channel

Direct sales, distributors and dealers, and online sales form the commercial channels. The supplied tables do not provide channel-specific values or CAGR; consequently, quantitative dominance is not assigned. The underlying product forecast nevertheless expands from USD 4,147.10 million in 2026 to USD 15,319.69 million in 2034.

Capital equipment typically requires technical installation and service, whereas standardized consumables permit broader replenishment channels. This distinction is material because devices carry a 17.85% CAGR while consumables carry 17.55% through 2034.

IVF Devices and Consumables Market Regional Outlook

North America IVF Devices and Consumables Market 

North America leads with USD 1,629.62 million in 2026, approximately 39.3% of regional revenue, rising to USD 5,941.10 million by 2034 at 17.55% CAGR. The U.S. provides a major procedural base, recording 435,426 ART cycles, 206,304 embryo transfers and 184,423 banking cycles in 2022.

Europe IVF Devices and Consumables Market 

Europe represents USD 1,214.25 million in 2026, approximately 29.3%, and reaches USD 4,375.83 million by 2034 at 17.38% CAGR. UK activity alone exceeded 100,000 treatment and freezing cycles in 2024, with IVF accounting for 76% and freezing cycles 17% of activity.

APAC IVF Devices and Consumables Market 

APAC reaches USD 694.50 million in 2026, approximately 16.8% of regional revenue, before increasing to USD 2,561.38 million by 2034 at 17.72% CAGR. China, Japan, India, Australia and South Korea form important clinical markets, while equipment and disposable-device demand benefits from expanding laboratory capacity.

Middle East and Africa IVF Devices and Consumables Market 

Middle East and Africa accounts for USD 344.69 million in 2026, approximately 8.3%, and is the fastest-growing supplied region at 18.05% CAGR, reaching USD 1,300.06 million in 2034. Gulf fertility hubs and expanding private healthcare infrastructure support equipment-intensive IVF laboratory development.

Latin America IVF Devices and Consumables Market 

Latin America represents USD 258.49 million in 2026, approximately 6.2%, advancing at 17.80% CAGR to USD 958.53 million by 2034. Brazil and Mexico constitute major procedural centers, while private fertility clinics underpin demand for imported laboratory equipment and recurring consumables.

Top players in Global IVF Devices and Consumables Market

1. CooperSurgical
2. Vitrolife Group
3. Nexpring Health
4. Esco Medical
5. Hamilton Thorne
6. FUJIFILM Irvine Scientific
7. Cook Reproductive Health
8. Kitazato Corporation
9. Genea Biomedx
10. Nikon Corporation
11. Thermo Fisher Scientific
12. Merck KGaA
13. Nidacon International
14. IVFtech
15. Planer

Top Two Companies

• CooperSurgical: A precise comparable device-and-consumable percentage is not publicly disclosed. As a positioning proxy, CooperSurgical reported USD 524.6 million in fiscal-2025 fertility revenue, up 3% from USD 511.3 million in 2024; this includes fertility products and services beyond the narrowly defined equipment/consumables scope and therefore should not be treated as audited market share. Its portfolio breadth across fertility consumables, equipment, donor-gamete and genomic services establishes a major global competitive position.

• Vitrolife Group: Comparable market share is likewise not separately disclosed. Vitrolife reported SEK 3,440 million in 2025 net sales, including SEK 1,368 million from Consumables and SEK 684 million from Technologies—approximately 40% and 20% of company revenue respectively. Consumables recorded 5% local-currency expansion, while the Americas represented 33% and APAC 29% of group revenue, supporting its strong international IVF positioning.

Recent Developments in Global IVF Devices and Consumables Market

• 2026: Vitrolife reported Q4 2025 sales of SEK 891 million, with Consumables increasing 10% and Technologies 6% in local currencies excluding discontinued operations.
• 2025: Esco Medical launched the MIRI M Multiroom IVF Incubator with up to 18 independent chambers and environmental stability while undocked for up to 30 minutes.
• 2025: Hamilton Thorne became part of Nexpring Health, combining more than 8 established reproductive-health brands including Cook Reproductive Health, Planer, IVFtech and Gynemed.
• 2025: An affiliate of Hamilton Thorne agreed to acquire FUJIFILM Irvine Scientific's ART and cytogenetics offerings, broadening integrated fertility media, consumables and laboratory capabilities.